X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Religare Enterprises - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs RELIGARE ENT. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

RELIGARE ENT. 
   Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES RELIGARE ENT. INDOCO REMEDIES/
RELIGARE ENT.
 
P/E (TTM) x 30.5 20.1 151.6% View Chart
P/BV x 3.6 0.3 1,263.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   RELIGARE ENT.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
RELIGARE ENT.
Mar-16
INDOCO REMEDIES/
RELIGARE ENT.
5-Yr Chart
Click to enlarge
High Rs360395 91.2%   
Low Rs249256 97.3%   
Sales per share (Unadj.) Rs119.0218.0 54.6%  
Earnings per share (Unadj.) Rs8.4-2.3 -356.8%  
Cash flow per share (Unadj.) Rs15.2-0.6 -2,624.9%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7190.0 37.2%  
Shares outstanding (eoy) m92.15203.33 45.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.5 171.5%   
Avg P/E ratio x36.4-138.9 -26.2%  
P/CF ratio (eoy) x20.0-561.0 -3.6%  
Price / Book Value ratio x4.31.7 251.6%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08366,184 42.4%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1679,336 23.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,96844,318 24.7%  
Other income Rs m40709 5.6%   
Total revenues Rs m11,00745,026 24.4%   
Gross profit Rs m1,56523,723 6.6%  
Depreciation Rs m633359 176.5%   
Interest Rs m6218,721 0.3%   
Profit before tax Rs m9095,351 17.0%   
Minority Interest Rs m0-1,085 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m0-2,533 0.0%   
Tax Rs m1392,215 6.3%   
Profit after tax Rs m771-477 -161.7%  
Gross profit margin %14.353.5 26.7%  
Effective tax rate %15.341.4 36.8%   
Net profit margin %7.0-1.1 -653.4%  
BALANCE SHEET DATA
Current assets Rs m5,72594,957 6.0%   
Current liabilities Rs m5,454103,036 5.3%   
Net working cap to sales %2.5-18.2 -13.5%  
Current ratio x1.00.9 113.9%  
Inventory Days Days625 1,308.1%  
Debtors Days Days7238 187.9%  
Net fixed assets Rs m5,30717,890 29.7%   
Share capital Rs m1842,033 9.1%   
"Free" reserves Rs m6,33133,999 18.6%   
Net worth Rs m6,51638,629 16.9%   
Long term debt Rs m1,323118,583 1.1%   
Total assets Rs m11,970274,293 4.4%  
Interest coverage x15.61.3 1,216.7%   
Debt to equity ratio x0.23.1 6.6%  
Sales to assets ratio x0.90.2 567.1%   
Return on assets %7.06.7 104.6%  
Return on equity %11.8-1.2 -958.8%  
Return on capital %12.413.0 95.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,14112 9,672.9%   
Net fx Rs m3,366-12 -28,521.2%   
CASH FLOW
From Operations Rs m886-21,540 -4.1%  
From Investments Rs m-1,7065,149 -33.1%  
From Financial Activity Rs m1,31618,531 7.1%  
Net Cashflow Rs m4972,139 23.2%  

Share Holding

Indian Promoters % 59.2 50.9 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.9 1,388.9%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 32.9 68.1%  
Shareholders   12,805 26,518 48.3%  
Pledged promoter(s) holding % 0.0 68.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TIMKEN INDIA  CENTURY PLYBOARDS  COMPACT DISC  TALWALKARS BETTER VAL.  INDIABULLS FIN. SER.  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Feb 19, 2018 11:47 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS